MAPT and neurodegenerative disease: Neither MD3.1 or MD2.2 stained other neurodegenerative disease brain samples without tau pathology, an MSA brain featuring α-synuclein aggregates, or an FTLD brain featuring TDP-43 aggregates (Fig. 7).